Regulatory Changes Are Shaping the Cost of GLP-1 Medications In December 2024, the U.S. Food and Drug Administration (FDA) announced the resolution of the tirzepatide shortage. Which is the active ingredient in Eli Lilly’s Mounjaro and Zepbound. During the shortage, compounding pharmacies were allowed to produce versions of tirzepatide to help meet demand. However, now that the shortage is resolved, the FDA is requiring ...
The Growing Problem of Medical Waste and Sharps Disposal Every year, millions of used needles and syringes are discarded, which can create significant environmental and public health risks. Individuals who self-inject medications, such as those managing diabetes, hormone therapy, or weight-loss treatments, often lack clear and sustainable options for disposing of their sharps. Traditional disposal methods, including placing ...
The rise of GLP-1 injectable medications, such as those used for diabetes management and weight loss, has been nothing short of a pharmaceutical phenomenon. In 2023 alone, the demand for GLP-1 meds skyrocketed, with global sales expected to exceed $12 billion by 2025, according to a report by Fortune Business Insights. It shows that there are more patients embracing injectables as part of their health and wellness journey. ...
